Analysis of Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation or Chemotherapy in Patients with Hematologic Diseases.
- Author:
Jin Hong YOO
1
;
Jung Hyun CHOI
;
Dong Gun LEE
;
Sumi CHOI
;
Wan Shik SHIN
;
Chun Choo KIM
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. jhyoo@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Invasive fungal infection;
Immunocompromised
- MeSH:
Amphotericin B;
Diagnosis;
Drug Therapy;
Follow-Up Studies;
Hematologic Diseases*;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Hospitalization;
Humans;
Mortality;
Multivariate Analysis;
Prognosis;
Respiratory System;
Retrospective Studies;
Sodium Glutamate
- From:
Infection and Chemotherapy
2004;36(1):40-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Invasive fungal infections (IFI) are one type of representing total infections in compromised patients. To analyze the characteristics and to determine the prognostic factors of IFI in patients with hematologic diseases undergoing hematopoietic stem cell transplantation (HSCT) and/or chemotherapy. METHODS: We retrospectively reviewed consecutive patients (n=122) who received antifungal treatment with the impression of fungal infection complicating post-HSCT or chemotherapy from March- 2000 to February-2001. RESULTS: Seventy-four out of 122 registered patients belonged to the IFI on the basis of EORTC/ MSG criteria. Six patients were proven IFI, 46 were probable, and 22 were in the category of possible one. The most commonly involved organ was lower respiratory tract (72/74). The mortality was 32.4%. Univariate analysis revealed duration of hospitalization, days to diagnosis of IFI, and total amount of amphotericin B as significant prognostic factors. But multivariate analysis determined only duration of hospitalization from these variables as an independently influencing factor on the prognosis. CONCLUSION: Invasive fungal infection is still the major threatening complication of HSCT and chemotherapy. Further follow-up and extension of this study is necessary to elucidate more prognostic factors.
